Overview

Safety Profile of Secotex ® in Patients With Benign Prostatic Hyperplasia

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The Objective of this study is to conduct a Prescription Event Monitoring (PEM) involving patients treated with Secotex® (Tamsulosin) in "real life" settings. The aim of a PEM is to monitor the safety profile of Secotex® in a cohort of patients with Benign Prostatic Hyperplasia as used in general practice
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Tamsulosin